Tractional retinal detachment in patient with proliferative diabetic retinopathy Tractional retinal detachment Anti VEGF diabetic retinopathy OCT
Conditions
Interventions
Intravitreal anti-VEGF (Bevacizumab, Aflibercept, Ranibizumab) injection on day0, day 30, day 60,Patient will be follow up with OCT on day 0, 30, 60 and 90
Experimental Drug,No Intervention No treatment
Anti VEGF injection,Control
Sponsors
Research Funds, Faculty of medicine, KKU
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age > 18 years 2. With the following characteristics 2.1) underlying disease of type 1 or type 2 diabetes mellitus 2.2) diagnosed with PDR with TRD requiring surgery 2.3) OCT scans on the enroll day with good interpretable quality showing fibrous traction on preretinal area and tractional retinal detachment 2.4) If two eyes are elligible, only one eye per patient (the eye with worse visual acuity) will be included in the study.
Exclusion criteria
Exclusion criteria: 1. Patient with center-involved DME with macular edema from component other than traction 2. Patient with severe anterior segment pathology precluding OCT scans, fundus examination (i.e. dense cataract, dense vitreous hemorrhage) 3. Previous intraocular surgery (except uncomplicated cataract surgery) 4. Previous Injection into study eyes within 6 months 5. Patient contraindicated to intravitreal injection (i.e endophthalmitis) 6. Patient with other ocular pathology causing possible neovascularization, retinal detachment or fibrous traction in study eyes (Traumatic retinal detachment, Uveitis, Retinal vascular disease, Congenital vitreoretinopathy 7. Patient denied intravitreal injection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of tractional degree 1 month OCT | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of detachment degree 1 month OCT | — |
Countries
Thailand
Contacts
Public ContactKanpirom Tangpontirak
student
Outcome results
None listed